This move is archived. Current quotes and coverage live on the stock page.
Get HBP alerts:
Helix BioPharma Corp. saw a notable decline in its stock price today, closing down 1.41%.
In today's trading session, Helix BioPharma Corp. (HBP.TO) closed at CA$1.40, reflecting a 1.41% drop. This decline raises concerns among investors about the company's financial health and future prospects.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$137.48M
52W high
$5.40
52W low
$1.10
1W change
-2.63%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 35.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+35.1% Upside
Current Price
C$1.85
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
67.2%
Annualized
90-Day Vol
65.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.21
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.96 | C$1.56 โ C$2.48 |
| 60 trading days | C$2.08 | C$1.50 โ C$2.89 |
| 90 trading days | C$2.21 | C$1.48 โ C$3.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Helix BioPharma continues to face challenges in securing capital and advancing its development objectives, which may impact stock performance in the near term.
Stock Down 1.41% Today
Helix BioPharma's market cap now stands at CA$108.46 million, reflecting investor concerns over its financial stability.
Bull case
If Helix BioPharma can secure the necessary funding and make progress on its clinical programs, there could be significant growth potential in the long run.
Bear case
Ongoing difficulties in attracting investment and a lack of positive news could lead to further declines in stock price, as seen in today's performance.
Market Performance Overview
Advertisement
Helix BioPharma Corp. closed at CA$1.40 today, down 1.41% from the previous trading session. This drop reflects ongoing investor skepticism about the company's financial results and capital acquisition efforts.
Investor Concerns
The absence of recent positive news and the company's struggle to secure funding have raised red flags for investors. Helix's market cap of CA$108.46 million suggests that many are wary of its future growth potential, especially in a challenging capital markets environment.
Looking Ahead
As Helix BioPharma navigates its operational and development challenges, investors should keep an eye on updates regarding funding and clinical advancements. The outcome of these efforts will be crucial in determining the stock's trajectory in the coming months. For more insights, visit our Helix BioPharma stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
